EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

A single-arm prospective phase I trial of 68Ga-PFBC01 PET/CT for multiple myeloma B cell maturation antigen imaging

Tingfei Gu, Zhao Chen, Bo Tang, Tianyao Wang, Qi Yang, Huihui Liu, Zeyin Liang, Qian Wang, Yang Zhang, Yuhua Sun, Mingyi Di, Tingting Yuan und 8 weitere

Journal of Clinical Investigation · 2026

DOI: 10.1172/jci207391 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Tingfei Gu und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine and. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Multiple Myeloma, B-Cell Maturation Antigen, Gallium Radioisotopes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Beijing Nova Program, National High Level Hospital Clinical Research Funding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND B cell maturation antigen (BCMA) is a key therapeutic target in multiple myeloma (MM), yet its whole-body in vivo distribution and role in disease assessment remain incompletely defined. We aimed to evaluate the safety, diagnostic performance, and clinical utility of a novel BCMA-targeted PET tracer, 68 Ga-PFBC01, in patients with plasma cell disorders. METHODS We conducted a single-center, prospective, single-arm phase I trial (ClinicalTrials.gov NCT06717113). Fifty patients underwent 68 Ga-PFBC01 PET/CT, including 40 with paired 18 F-FDG PET/CT for head-to-head comparison. Primary outcomes included diagnostic performance (sensitivity, specificity, PPV, NPV, and interreader agreement). Secondary outcomes included correlations with clinical biomarkers, treatment response assessment, impact on clinical decision-making, and safety. RESULTS 68 Ga-PFBC01 PET/CT demonstrated superior diagnostic performance compared with 18 F-FDG PET/CT (sensitivity 96.9% versus 84.6%; specificity 71.4% versus 60.0%). Quantitative PET-derived tumor burden correlated with M protein ( R = 0.325, P = 0.026), free light chains ( R = 0.340–0.437, P ≤ 0.015), soluble BCMA ( R = 0.433, P = 0.050), and bone marrow plasma cells ( R = 0.682, P < 0.001). Imaging findings altered clinical management in multiple cases, enabling both therapy escalation and deescalation. Blood-pool uptake strongly correlated with soluble BCMA ( R = 0.899, P < 0.001) and overall disease burden ( R = 0.736, P < 0.001). No serious tracer-related adverse events were observed; 2 patients (4%) experienced mild events. CONCLUSION 68 Ga-PFBC01 PET/CT provides biologically specific, whole-body assessment of MM, outperforming 18 F-FDG and enabling integrated evaluation of tumor burden and systemic disease activity, with direct implications for clinical decision-making. TRIAL REGISTRATION ClinicalTrials.gov NCT06717113. FUNDING National Natural Science Foundation of China (82472018, 82402320), Beijing Nova Program (20240484725), National High Level Hospital Clinical Research Funding (Interdisciplinary Research Project of Peking University First Hospital, 2024IR07, Scientific and Technological Achievements Transformation Incubation Guidance Fund Project of Peking University First Hospital, 2025CX38, 2024CX18). Research Achievement Transformation Project of Peking University First Hospital, 2025ZH02), Clinical Medicine Plus X - Young Scholars Project of Peking University, the Fundamental Research Funds for the Central Universities (PKU2026PKULCXQ038).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyMultiple MyelomaB-Cell Maturation AntigenGallium RadioisotopesRadiopharmaceuticalsHumansFemaleMiddle AgedMaleProspective StudiesAgedAdult

Stichwörter der Autor:innen

Clinical ResearchDiagnostic imagingHematologyOncology

Substanzen

B-Cell Maturation AntigenGallium RadioisotopesRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Nuclear Medicine and.
  • Department of Hematology, Peking University First Hospital, Beijing, China.
  • Department of Genetic Engineering, Beijing Institute of Biotechnology, Beijing, China.
  • Department of Pathology, Peking University First Hospital, Beijing, China.

Förderung

  • National Natural Science Foundation of China
  • Beijing Nova Program
  • National High Level Hospital Clinical Research Funding

Zitieren

APA

Gu, T., Chen, Z., Tang, B., Wang, T., Yang, Q., Liu, H., Liang, Z., Wang, Q., Zhang, Y., Sun, Y., Di, M., Yuan, T., Qiu, Y., Du, Y., Song, L., Wu, S., Wang, W., Xu, X., Dong, Y., & Kang, L. (2026). A single-arm prospective phase I trial of 68Ga-PFBC01 PET/CT for multiple myeloma B cell maturation antigen imaging. Journal of Clinical Investigation. https://doi.org/10.1172/jci207391

Vancouver

Gu T, Chen Z, Tang B, Wang T, Yang Q, Liu H, et al. A single-arm prospective phase I trial of 68Ga-PFBC01 PET/CT for multiple myeloma B cell maturation antigen imaging. Journal of Clinical Investigation. 2026. doi:10.1172/jci207391

BibTeX
@article{Gu2026,
  author = {Gu, Tingfei and Chen, Zhao and Tang, Bo and Wang, Tianyao and Yang, Qi and Liu, Huihui and Liang, Zeyin and Wang, Qian and Zhang, Yang and Sun, Yuhua and Di, Mingyi and Yuan, Tingting and Qiu, Yongkang and Du, Yimeng and Song, Lele and Wu, Shengnan and Wang, Wei and Xu, Xiaojie and Dong, Yujun and Kang, Lei},
  title = {A single-arm prospective phase I trial of 68Ga-PFBC01 PET/CT for multiple myeloma B cell maturation antigen imaging},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  doi = {10.1172/jci207391}
}
Kostenlos starten →